Early treatment of pediatric Crohn’s disease with anti-TNF medications, such as infliximab and adalimumab, can significantly reduce the risk of developing perianal fistulas, a debilitating complication. Research led by the University of Michigan confirmed these findings, demonstrating the effectiveness of anti-TNF therapy in preventing fistulas, which could improve patient outcomes and reduce long-term costs. To learn more about this groundbreaking study and its potential to transform Crohn’s disease treatment, read the full article.
